Pot is also called weed, grass, and marijuana, but its proper name is cannabis or decarbed marijuana extracts. Through the years, many studies assert that some compounds found in bud have medicinal usage, particularly in terminal diseases like cancer and AIDS. This began a ferocious debate over the advantages and disadvantages of using medical marijuana. The report was comprehensive but didn’t offer a clear cut yes or no response. The other medical marijuana issue peaks frequently cite a portion of this report in their advocacy arguments. But, even though the report explained many things, it never depended on the controversy.
Let us look at the problems that encourage why medical marijuana ought to be legalized.
Pot is a naturally occurring herb that has been used by South America and Asia as an herbal medicine for millennia. In this day and age, after the natural and organic are significant well-being buzzwords, a naturally occurring herb such as bud could be more attractive and safer for users than synthetic medications.
Marijuana has Robust Therapeutic Potential
Several studies, as outlined from the IOM report, researchers have discovered that cannabis may be utilized as analgesic, e.g., to deal with pain. A couple of studies demonstrated that THC, a bud element, successfully treats chronic pain experienced by cancer patients. But studies on severe pain like those experienced during operation and injury have inconclusive reports. A couple of reviews, also outlined from the IOM report, have shown that some bud elements possess antiemetic properties and are, consequently, effective against nausea and vomiting, which are common side effects of cancer chemotherapy and radiation treatment. Some investigators are convinced that cannabis has some therapeutic potential against neurological disorders like multiple sclerosis. Particular compounds extracted from bud have strong therapeutic potential. Cannabidiol (CBD), a significant part of marijuana, was proven to possess antifungal, anticancer, and antioxidant properties. Additional cannabinoids have been shown to stop sizeable intraocular pressure (IOP), a significant risk factor for glaucoma. The US FDA has accepted medicines that contain active ingredients found in bud but happen to be synthetically produced from the lab.
Marijuana Policy Project (MPP)
Some of the significant proponents of medical marijuana would be that the Marijuana Policy Project (MPP), a US-based business. Lots of medical professional societies and associations have voiced their support. For example, The American College of Physicians advocated a re-evaluation of this Schedule I classification of marijuana in their 2008 place paper. ACP also expresses its strong support for research into the therapeutic purpose of marijuana in addition to exemption from federal criminal prosecution, civil accountability, or specialist sanctioning for doctors who prescribe or dispense medical marijuana based on state law. In the same way, protection against civil or criminal penalties for individuals using medical marijuana as allowed under state lawsMedical marijuana is lawfully utilized in several developed nations. The debate of if they could do it, why not? Countries like Canada, Belgium, Austria, the Netherlands, the UK, Spain, Israel, and Finland have hailed the therapeutic use of marijuana under rigorous prescription management. Some nations in the USA will also be allowing exemptions.
Lack of Information on Safety and Efficiency
Drug regulation relies on security. The security of marijuana and its elements still must be established. Efficacy only includes second. Even if marijuana has some beneficial health effects, the benefits need to outweigh the risks for this to be considered for clinical usage. Unless marijuana is demonstrated to be better (safer and more efficient ) than drugs currently available on the current market, its acceptance for medical use might be a very long shot. According to the testimony of Robert J. Meyer of the Department of Health and Human Services, using a medication or medical therapy, without understanding how to use it even if it’s successful, doesn’t benefit anybody. Merely having accessibility, without needing safety, efficiency, and sufficient use of information doesn’t help patients.
Unknown Compound Elements
Medical marijuana can simply be readily accessible and affordable in herbal kind. As with other herbs, bud falls under the class of botanical products. Unpurified horticultural products face many issues, such as lot-to-lot consistency, dose conclusion, potency, shelf life, and toxicity. To completely characterize the various elements of marijuana could cost as much money and time, the expenses of these drugs that will come from it could be too significant. Presently, no pharmaceutical company appears interested in investing cash in isolating more curative components from bud beyond what’s currently available on the industry.It might not be as addictive as hard drugs like cocaine; it cannot be denied that there’s a possibility of chemical abuse connected with marijuana. It was shown by some studies, as outlined in the IOM report.
Insufficient Secure Delivery System
The most typical kind of delivery of marijuana is via smoking. Medical authorities won’t ever accept this kind of transportation. Reliable and safe delivery methods in the type of vaporizers, nebulizers, or inhalers are still in the testing phase.If marijuana has therapeutic consequences, it’s just addressing the symptoms of specific diseases. It doesn’t cure or treat these disorders. Given it is effective against those symptoms, you will find already drugs available that work just as well or better still, minus the side effects and danger of misuse related to marijuana.
The report certainly discouraged using smoked marijuana but gave the nod to marijuana usage via a health inhaler or vaporizer. What’s more, it advocated more funds from the research of their efficacy and safety of cannabinoids.So what stands in the method of clarifying the questions caused by the IOM report? The health authorities don’t appear to be interested in getting another review. There’s limited information available, and anything can be obtained biased towards security issues on the adverse effects of smoked marijuana. Data on effectiveness mainly include research on synthetic cannabinoids (e.g., THC). This disparity in data makes a goal risk-benefit appraisal difficult.
Clinical research on marijuana is difficult to run because of restricted funding and rigorous regulations. Often, it’s not clear how to specify medical marijuana as advocated as opposed by many classes. Does this only refer to using this botanical product bud, or does this include synthetic cannabinoid elements (e.g., THC and derivatives)? Synthetic cannabinoids (e.g., Marinol) available on the market are incredibly costly, forcing people towards the less expensive cannabinoid in the kind of marijuana. The problem is further obscured by conspiracy theories between the pharmaceutical industry and drug regulators.In summary, medical marijuana’s future and the payoff of this argument would rely upon broader and comparable scientific studies. An upgrade of this IOM report soon is well-needed.